Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25517756 | 1.00 | KDM4E (0.53) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL25517754 | 0.93 | KDM4E (0.47) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL23451136 | 0.91 | TSHR (0.47) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL23452878 | 0.91 | KDM4E (0.44) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL13750053 | 0.87 | EPHX1 (0.53) | PLA2G2ACA12CA1CA2CA9 | |
| SCHEMBL22906226 | 0.87 | CA12 (0.42) | KDM4EMAPK1HIF1APLA2G2ACA12 | |
| SCHEMBL13208810 | 0.86 | MTNR1A (0.42) | KDM4EMAPK1HIF1APLA2G2ACA12 | |
| SCHEMBL23451009 | 0.85 | PLA2G2A (0.43) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL21893205 | 0.85 | KDM4E (0.55) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL20385669 | 0.84 | PLA2G2A (0.38) | KDM4EMAPK1HIF1APLA2G2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091985-A1 | COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE | DTX PHARMA, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023086978-A2 | BRANCHED TRIPLE LIPID-MODIFIED NUCLEIC ACID COMPOUNDS | DTX PHARMA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086979-A1 | STAGGERED TRIPLE LIPID-MODIFIED NUCLEIC ACID COMPOUNDS | DTX PHARMA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20220047621-A1 | RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION | AMGEN INC. (US) | 2022-02-17 | — | — | US | disclosed |
| EP-2860251-B1 | Aptamer therapeutics useful in the treatment of complement-related disorders | ARCHEMIX LLC (US) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047621-A1 | RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION | MARCKS, FABP1, MFAP1 | KDM4E 3958/4885MAPK1 1919/4885HIF1A 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.